The Positive Prognostic Value of Stress Echocardiography - AMPHIPOLIS STUDY

Launched by HELLENIC SOCIETY OF CARDIOLOGY · Feb 16, 2025

Keywords

ClinConnect Summary

The AMPHIPOLIS STUDY is a clinical trial designed to better understand how effective stress echocardiography (a heart test that shows how well your heart functions under stress) is in predicting health outcomes for patients with coronary artery disease and myocardial ischemia (a condition where your heart doesn't get enough blood). In this study, researchers will enroll 390 patients who have recently had a positive stress echo test. These patients will then undergo a more detailed heart imaging test called coronary angiography, and they will be followed for at least six months to see how they do in terms of heart-related health issues, including serious events like heart attacks or cardiovascular death.

To be eligible for the trial, participants should be adults who have had a recent positive stress echocardiogram indicating some level of heart strain. However, certain conditions would exclude someone from participating, such as severe heart failure, significant valvular heart disease, or other serious health issues that could affect life expectancy. Participants can expect to have their heart health closely monitored and contribute to important findings that could help improve care for patients with heart disease in the future. The trial is currently recruiting, and both men and women of various ages are welcome to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with recent stress echocardiography positive for any extent of myocardial ischemia
• Exclusion Criteria:
• • 1. HFrEF requiring viability study.
• • 2. Any symptomatic valvular disease causing symptoms.
• • 3. Established or suspected cardiomyopathy.
• • 4. Concomitant chronic diseases reducing life expectancy (active cancer, severe liver impairment, auto-immune diseases etc).
• • 5. Recent acute coronary syndrome the last week.